Navigation Links
Acella Pharmaceuticals, LLC Announces Its Acquisition of the PRENATE® Family of Trademarks and Associated Intellectual Property
Date:1/5/2012

ATLANTA, Jan. 5, 2012 /PRNewswire/ -- Acella Pharmaceuticals, LLC announced its acquisition of the PRENATE® family of trademarks and other associated intellectual property.  The worldwide trademarks included in the sale were the core PRENATE® mark, in addition to PRENATE DHA®, PRENATE ESSENTIAL® and PRENATE ELITE®. PRENATE® is a leading U.S. prenatal brand.

Acella has entered into a separate agreement with Avion Pharmaceuticals, LLC, Acella's sister company, to market and sell products under PRENATE®.

"We are extremely pleased about the acquisition of PRENATE," stated Mark Pugh, CEO of Acella Pharmaceuticals. "For many years, PRENATE has been a gold standard for improving the nutritional status of women throughout pregnancy and in the postnatal period, for both lactating and non-lactating mothers. The addition of PRENATE fits solidly with our core strategic vision of establishing ourselves as a leading provider in the women's health and nutritional spaces."

The American Institute of Medicine, in its publication, "Nutrition During Pregnancy" (1990 Nat'l Academy Press) stated its consensus on the use of dietary supplements before, during and after pregnancy.  The American Institute of Medicine further noted the lack of sufficient folic acid in the average American diet, for which they recommended supplementation. Acella's current portfolio of PRENATE products will assist women in supplementing this dietary need.

Under the terms of its agreement with Acella, Avion is in the process of growing a national sales force of 80 sales associates to immediately and actively promote the PRENATE® vitamin family to physicians across the U.S.

H.I.G. WhiteHorse completed the financing for the acquisition.  H.I.G WhiteHorse provides debt financing to middle market companies in the U.S. and Europe.  H.I.G WhiteHorse has a broad investment mandate to provide senior and subordinated debt for refinancing, growth capital, acquisitions and buyouts.  Credit facilities typically range in size from $15 to $100 million for companies with revenues of $50 million or more.  Jefferies & Company, Inc. acted as Exclusive Financial Advisor to Acella.

About Acella Pharmaceuticals, LLC.
Acella develops, markets, sells and distributes a broad portfolio of non-branded pharmaceutical and other products in the areas of Dermatology, Women's Health, Pediatrics and other applications. Acella specializes in identifying and bringing to market quality, affordable products to customers and patients. For additional information please contact Acella at 678-325-5189.

About Avion Pharmaceuticals, LLC.
Avion is a Specialty Pharmaceutical company that develops and markets a growing portfolio of innovative, branded pharmaceutical and dietary supplement products in the Women's Health and Dermatology areas. Avion focuses on identifying opportunities to acquire and enhance the market potential of innovative, commercially available dietary supplement products, and therapeutics and late-stage development drugs to fulfill unmet medical and dietary needs.


'/>"/>
SOURCE Acella Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Brookstone Pharmaceuticals, LLC becomes Acella Pharmaceuticals, LLC
2. Omthera Pharmaceuticals, Inc. to Present at the 30th Annual J.P. Morgan Healthcare Conference
3. Kinex Pharmaceuticals Acquires Rights for Technology and Products from Hanmi Pharmaceuticals, in United States and European Union Territories
4. Block & Leviton LLP Investigates ISTA Pharmaceuticals, Inc.s Board of Directors for Possible Breaches of Fiduciary Duty
5. Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in XIAFLEX® Study for Frozen Shoulder Syndrome
6. AMG 277 Discriminates Against S1P3 Receptor by 50-fold. S1P1 Lead Compounds Will Be Offered for Sale at a December 8, 2011 Sealed Bid Sale. Assets Generated by Epix Pharmaceuticals, Inc. and Amgen.
7. Kahn Swick & Foti, LLC Announces Class Action Settlement on Behalf of Purchasers of Publicly-Traded Securities of Acura Pharmaceuticals, Inc. -- ACUR
8. Pacira Pharmaceuticals, Inc. Announces Completion of Follow-on Offering of Common Stock and Exercise of Over-Allotment Option
9. Omthera Pharmaceuticals, Inc. to Present at the 23rd Annual Piper Jaffray Health Care Conference
10. Pacira Pharmaceuticals, Inc. Announces Pricing of Follow-On Offering
11. S1P1 Lead Compounds, Assets Generated by Epix Pharmaceuticals, Inc. and Amgen, Will Be Offered for Sale at a December 8, 2011 Sealed Bid Sale. Target Rationale for S1P1 Agonists Explained.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... , Oct. 12, 2017 AVACEN Medical ... the company with their  2017 New Product Innovation Award ... on extensive primary and secondary medical device market research by ... through its first-to-market OTC, drug-free pain relief product, the AVACEN ... approach to treating fibromyalgia widespread pain. ...
(Date:10/11/2017)... 2017  True Health, a leader in integrated ... during National Breast Cancer Awareness month to educate ... Research recently published ... more than 10 million American women are at ... or BRCA2 and have not had testing. These mutations ...
(Date:10/5/2017)... 2017  In response to the nationwide opioid ... Surgeons (AAOMS) released prescribing recommendations that urge ibuprofen ... as a first-line therapy to manage a patient,s ... Recognizing the value and importance of ... Prescribing: Acute and Postoperative Pain Management" stresses that ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “America On ... Christian identity. “America On The Brink” is the creation of published author, William ... several great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... ... 2017 , ... The company has developed a suite of ... authorities worldwide. From Children’s to Adults 50+, every formula has been developed by ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, Preservative ...
(Date:10/12/2017)... Rockville, Maryland (PRWEB) , ... October 12, 2017 ... ... a magnetic drug delivery system that we intend to develop to enable prevention ... regimens can lead to severe hearing loss, especially in pediatric patients. For cisplatin, ...
(Date:10/12/2017)... FL (PRWEB) , ... October 12, 2017 , ... On ... holding a treadmill relay – Miles by Moonlight to raise money for the American ... $300 or more. , Teams will work together to keep their treadmills moving ...
(Date:10/12/2017)... ... October 12, 2017 , ... Vohra Chief Medical Officer Dr. ... colleagues, skilled nursing facility medical directors and other clinicians at various events in ... , "At many of these conferences we get to educate other physicians, facility ...
Breaking Medicine News(10 mins):